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Low MAD2 expression levels associate with reduced progression free survival (PFS) 
in patients with high-grade serous epithelial ovarian cancer (EOC). 
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Abstract   
 
Epithelial ovarian cancer (EOC) has an innate susceptibility to become chemo-resistant.  
Up to 30% of patients do not respond to conventional chemotherapy (paclitaxel (Taxol®) 
in combination with carboplatin) and of those who have an initial response, many patients 
relapse.  Therefore, an understanding of the molecular mechanisms that regulate cellular 
chemotherapeutic responses in EOC cells has the potential to impact significantly on 
patient outcome. The mitotic arrest deficiency protein 2 (MAD2), is a centrally important 
mediator of the cellular response to paclitaxel.  MAD2 immunohistochemical analysis 
was performed on 82 high-grade serous EOC samples.  A multivariate Cox regression 
analysis of nuclear MAD2 IHC intensity adjusting for stage,  tumour grade and optimum 
surgical debulking revealed that low MAD2 IHC staining intensity was significantly 
associated with reduced progression free survival (PFS) (p = 0.0003) with a hazard ratio 
of 4.689.  The in vitro analyses of 5 ovarian cancer cell lines demonstrated that cells with 
low MAD2 expression were less sensitive to paclitaxel.  Furthermore, paclitaxel induced 
activation of the spindle assembly checkpoint (SAC) and apoptotic cell death was 
abrogated in cells transfected with MAD2 siRNA.  In silico analysis identified a miR-433 
binding domain in the MAD2 3’UTR which was verified in a series of experiments.  
Firstly, MAD2 protein expression levels were downregulated in pre-miR-433 transfected 
A2780 cells.  Secondly, Pre-miR-433 suppressed the activity of a reporter construct 
containing the 3′-UTR of MAD2.  Thirdly, blocking miR-433 binding to the MAD2 
3’UTR protected MAD2 from miR-433 induced protein downregulation.  Importantly, 
reduced MAD2 protein expression in pre-miR-433 transfected A2780 cells rendered 
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these cells less sensitive to paclitaxel.  In conclusion, loss of MAD2 protein expression 
results in increased resistance to paclitaxel in EOC cells.  Measuring MAD2 IHC staining 
intensity may predict paclitaxel responses in women presenting with high-grade serous 
EOC.   
 
 
Key words:  microRNA, MAD2, chemo-resistance, epithelial ovarian cancer, paclitaxel. 
 
 
 
 
 5 
Introduction 
 
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy worldwide 
with most patients diagnosed with advanced disease at primary presentation (1).  
Cytoreductive surgery followed by a combination of platinum based and paclitaxel 
(Taxol®) chemotherapy is the first line treatment strategy currently in use.  Most 
advanced stage patients respond to this treatment modality (2).  However, 70% of women 
will relapse and the five-year survival rate is below 25% for patients diagnosed with stage 
III-IV EOC (2).  Cellular chemotherapeutic resistance is a major contributor to poor 
patient response and reduced overall survival in patients with ovarian tumours (3).  
Therefore, an understanding of the molecular mechanisms that regulate cellular 
chemotherapeutic responses has the potential to impact significantly on patient outcome. 
 
The taxane, paclitaxel, is a microtubule-stabilising agent that functions primarily by 
interfering with the spindle microtubule dynamics causing cell cycle arrest and apoptosis 
(4).  Cell cycle arrest is achieved by the activation of the spindle assembly checkpoint 
(SAC) resulting in cellular arrest in the G2-M phase of the cell cycle.   Specifically the 
SAC ensures the correct alignment and segregation of chromosomes into daughter cells 
exiting mitosis (5).  Microtubule dynamics are essential to this process and appropriate 
tension across the mitotic spindle is required to silence the SAC which causes sister 
chromatids to separate thereby facilitating mitosis (6).  In the presence of mitotic defects, 
cell death can be triggered during mitosis, or after the cell has exited mitosis (7).   
Chemo-resistance to paclitaxel can be attributed to functional aberrations in a variety of 
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molecular pathways governing cell cycle progression, growth promotion and the 
activation of apoptosis resulting in poor patient response to paclitaxel-based regimens (4). 
  
 The mitotic arrest deficiency protein 2 (MAD2), is a key regulator of the SAC pathway 
(8).  MAD2 protein expression is relatively unchanged throughout the cell cycle with 
SAC activation occurring through the association of MAD2 with MAD1 and the APC 
complex (APC/C) (9, 10). The cell cycle regulated phosphorylation of MAD2 modulates 
a conformational change in MAD2 that causes MAD1 and APC/C binding (10).  
Importantly, reduced MAD2 protein expression results in attenuated SAC responses in a 
number of cell models (11, 12) and subsequent drug resistance to paclitaxel (13-15).  
Although reduced MAD2 expression has been reported in human cancer (16, 17), the 
mechanisms underlying MAD2 down-regulation remain elusive.  Importantly, mutations 
in the MAD2 gene are reportedly rare in human cancer (18, 19) and we have previously 
shown that downregulation of MAD2 in cancer is not associated with promoter 
hypermethylation (20). 
 
In this study we have examined the immunohistochemical levels of MAD2 protein 
expression in 82 patient samples from a series of 45 full face formalin fixed paraffin 
embedded (FFPE) high-grade serous EOC sections of similar stage and grade and in a 
separate cohort of 37 high-grade serous EOC samples represented on a previously 
published tissue microarray (TMA) platform (21).  Our in vitro analyses have 
demonstrated a central role of MAD2 in the activation of mitotic cell death by paclitaxel.  
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Moreover we report for the first time, the downregulation of MAD2 by the microRNA, 
miR-433 that results in an attenuated cellular response to paclitaxel. 
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Materials and Methods 
Patients, tissue specimens and histopathologic data.  A total of 82 patients from 2 
independent patient cohorts were analysed in this study. 
Full face paraffin embedded sections from 45 high-grade serous carcinoma specimens 
were obtained from patients undergoing laparotomy for ovarian cancer in St. James’s 
Hospital, Dublin Ireland (patient cohort 1).  Informed consent was obtained from each 
patient by the research team prior to surgery with ethical approval received from the St. 
James’s Hospital/The Adelaide and Meath Hospital, Dublin Incorporating The National 
Children's Hospital Research Ethics Committee, Dublin, Ireland.  Tumours were staged 
according to the International Federation of Gynecology and Obstetrics (FIGO) staging 
system. Clinicopathological details of the specimens are shown in Table 1.  All patients 
received adjuvant carboplatin/paclitaxel chemotherapy.   
Thirty seven additional cases of high-grade serous EOC (patient cohort 2) which had 
been part of a previous study were also analysed (21).   Clinicopathological details of the 
specimens are shown in Table 1.  All patients were treated with platinum-based therapy 
alone or paclitaxel and platinum.  
Patient charts were monitored retrospectively and follow-up information was available 
including age, optimum surgical debulking (< 1 cm) and time to recurrence.  Progression 
free survival (PFS) for each patient was calculated from the date the sample was taken to 
the date of recurrence. 
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MAD2 Immunohistochemistry (IHC).  Five micron sections were immunostained with 
the MAD2 monoclonal antibody (BD Transduction Laboratories) at a dilution of 1:100 
on an automated platform (Bond™ system – Leica MicroSystems™, Newcastle, U.K.) as 
previously described (20). 
Manual MAD2 IHC Scoring.  IHC expression was quantified in patient cohort 1 (n = 45 
full face sections) and in patient cohort 2 (n = 37 on a TMA) by 2 independent observers 
(SP & AM, SP & BM, respectively).  The full face sections and the TMA cores were 
scored manually based on intensity of nuclear staining (1+ -negative, 2+ -weak and 3+ -
moderate and 4+ -strong).  In cases where the 2 observers differed, slides were re-
evaluated jointly by both observers and a consensus was reached.  The poor quality of 
one set of the ovarian tumour cores resulted in its exclusion from subsequent analyses.  
Tissue Culture.  The ovarian cancer cell lines, ovca432 and ovca433 were a kind gift 
from R. Bast, UT-MDAnderson Cancer Center and the Dana Faber Cancer Institute, 
USA.  The ovarian cancer cell lines were routinely cultured in MEM medium (Sigma) 
supplemented with 10% (v/v) FCS, 100 g streptomycin, 100 units/ml penicillin 0.3 
mg/mL glutamine, and 1% sodium pyruvate.  UPN251, ovcar7 and A2780 ovarian cancer 
cell lines were a kind gift from Robert F. Ozols, Fox Chase Cancer Center, USA.  These 
cell lines were cultured in RPMI 1640 supplemented with 10% (v/v) FCS, 100 g 
streptomycin, 100 units/ml penicillin 0.3 mg/mL glutamine.  The cell lines were 
maintained at 37C in a humidified incubator containing 5% CO2 and were routinely 
tested and shown negative for mycoplasma contamination. 
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RNA extraction.  The 45 Full face FFPE high-grade serous ovarian carcinoma sections 
(patient cohort 1) were H&E-stained and pathologically reviewed (SP).  Where tumour 
cell density was > 90%, whole sections were taken for miRNA analysis.  In cases where a 
tumoural stroma component was significantly present, areas were macro-dissected to 
enrich for the epithelial population.  Total RNA was isolated using the RNeasy FFPE Kit 
(Qiagen).  For the cell lines, RNA was extracted using the guanidine-based TRIzol™ 
reagent according to the manufacturer's instructions. 
 
qRT-PCR (Quantitative Real-Time PCR (TaqMan®).  MAD2 and hsa-miR-433 were 
sourced from ABI as Assay-On-Demand Gene Expression Assays and total RNA 
analysed by qRT-PCR on the ABI PRISM 7900 Sequence Detection System, mRNA 
levels were determined using the standard curve method (ABI Prism 7700 Sequence 
Detection System User Bulletin no. 2) and quantified using the TaqMan® comparative 
CT method of analysis as previously described  (20).  
 
Transient transfections.  Pre-miR-433 and scrambled control microRNAs were 
purchased from Applied Biosystems.  MAD2 siRNA and scrambled controls were 
purchased from Dharmacon and MAD2 morpholino and scrambled morpholino oligos 
were sourced from Gene-tools©.  400 nM of the pre-MiRs, 100 nM of siRNA or 10 M 
morpholino oligos were incubated with hiperfect (Qiagen) for 20 min at room 
temperature and mixed into a cell suspension (3.6 x 105 cells).  Cells were then plated 
onto 6 and 96 well plates and maintained in the presence of transfection mix for 2h before 
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changing the medium to full growth media.  Cells were treated with 10 and 50 nM 
paclitaxel the following day for 24h. 
 
SDS-PAGE and western blotting. Whole cell lysates were prepared using RIPA buffer. 
Samples were normalised for total protein, resuspended in reducing sample buffer, and 
separated by SDS-PAGE (22). Proteins were then electrophoretically transferred to a 
nitrocellulose membrane (100 V for 60 min) and analysed with antibodies raised against 
MAD2 (BD Transduction Laboratories), cyclin B1, Poly (ADP-ribose) polymerase 
(PARP), phospho(ser10)-Histone H3, cleaved caspase 3 (Cell Signalling) and -actin 
(Sigma).   Horseradish peroxidase-conjugated secondary antibodies (DakoCytomation) 
were used in conjunction with a ECL chemiluminescence detection system (Pierce). 
 
Cell viability assay.  Ovarian cancer cells treated with paclitaxel (10 and 50 nM) for 24 h 
and 48 h were analysed by the MTT assay as previously described (20).   
 
Luciferase reporter assay.  The pMIR-REPORT miRNA expression reporter vector 
system (Applied Biosystems) was used to construct a reporter plasmid containing 500 bp 
of the MAD2 mRNA transcript containing the putative miR-433 binding domain in the 
3’UTR according to manufacturer’s instructions with primers shown in table 2.  Cells 
were transfected with pre-miR-433 or scrambled control pre-miRs as outlined above. 
After 24 h, cells were co-transfected with the MAD2-pMIR-REPORT and TK renilla 
reporter plasmids.  MAD2-pMIR-REPORT luciferase activity was measured as 
previously described by Murphy et al., 2008 (23).    
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Statistical analyses. All data are presented as means ± SE for at least three independent 
experiments. Data analysis was performed using Microsoft Excel and SAS version 9 
(SAS Institute Inc, Cary, NC, USA).  The student’s t test was used for comparison of 
means and Kaplan Meier survival curve with log rank test are shown for PFS based on 
IHC staining intensity 1+ and 2+ compared to 3+ and 4+.  The effect of stage, tumour 
grade and optimum debulking on MAD2 IHC staining intensity was assessed in a 
multivariate Cox regression analysis.   
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Results 
 
Low MAD2 nuclear staining intensity is associated with reduced PFS in high-grade 
serous EOC post chemotherapy.  A total of 82 patient samples comprising of 45 full 
face FFPE high-grade serous ovarian carcinoma sections and a TMA representing an 
additional 37 FFPE tumour cores were immunohistochemically stained for MAD2.  
MAD2 stained the nucleus of ovarian epithelial cancer cells with varying degrees of 
intensity (Figure 1a).  In addition, MAD2 negative and positive cancer cells were evident 
in the same tumour (Figure 1a).  The Kaplan Meier survival curve for MAD2 IHC 
staining intensity and PFS demonstrated that low MAD2 IHC intensity is significantly 
associated with a reduced PFS (log rank p= 0.0005, Hazard ratio (HR) 2.75) (Figure 1b).  
In a multivariate Cox regression analysis adjusting for stage, grade and optimum surgical 
debulking, the association between low MAD2 IHC and PFS remained independently 
statistically significant (Log Rank p=0.0003) with an increased HR of 4.689.   
 
Ovarian cancer cell lines expressing high levels of MAD2 are more sensitive to 
paclitaxel.  MAD2 expression was assessed in 5 EOC cell lines by qRT-PCR (Figure 2a) 
and western blot analyses (Figure 2b).  MAD2 mRNA (Figure 2a) and protein levels 
(Figure 2b) were greatest in the A2780 EOC cell line.  The A2780 cell line was 
previously shown to be sensitive to paclitaxel at concentration of 1.4 nM (24).  The dose 
response curve for loss of cell viability at 48 h demonstrated that A2780 cells were more 
sensitive to paclitaxel compared to the other cell lines (Figure 2c).  However, MAD2 
expression levels and the effects of paclitaxel on cellular viability in the EOC cells are 
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not linear.  Specifically, MAD2 expression in UPN251 and ovcar7 is higher than MAD2 
expression in ovca432 and ovca433 (Figure 2a and 2b).  This however does not result in a 
greater loss of cell viability in response to paclitaxel (Figure 2c).   
 
To determine if the reduction of the cell viability measured in Figure 2c may reflect the 
anti-proliferative action, or the apoptotic action of paclitaxel, we have investigated 
paclitaxel activation of the SAC and induced mitotic arrest by western blot analysis for 
cyclin B1 stabilisation and phospho(Ser10)-Histone H3 (Figure 3a) (25, 26).  Paclitaxel 
induced apoptosis was assessed  by western blot analyses for PARP and cleaved caspase 
3 (Figure 3b) (27).  The treatment of A2780 cells with 50 nM paclitaxel for 24 h induced 
cyclin B1 stabilisation and phosphorylation of serine 10 on Histone H3 indicating the 
activation of the SAC and a sustained mitotic arrest (Figure 3a).  Conversely, the action 
of 50 nM paclitaxel for 24 h resulted in a diminished cyclin B1 stabilisation in ovcar7, 
ovca432 and ovca433 cells when compared with A2780 cells and failed to cause mitotic 
arrest in these cells evidenced by the absence of Histone H3 phosphorylation at 24 h 
(Figure 3a) and 48 h (data not shown).  Paclitaxel did not cause cyclin B1 stabilisation or 
Histone H3 phosphorylation in UPN251 cells indicating additional defects in activation 
of the SAC response in this cell line (Figure 3a).  Cyclin B1 stabilisation and Histone H3 
phosphorylation was not detected in any of the cell lines treated with 10 and 50 nM 
paclitaxel for 48 h (data not shown). 
 
Activation of the SAC which resulted in a sustained mitotic arrest by paclitaxel in A2780 
cells (Figure 3a) also resulted in PARP and caspase 3 cleavage at 24 h (data not shown) 
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and 48h (Figure 3b).  This data demonstrates the activation of paclitaxel induced cell 
death during mitosis as previously described (15).  Paclitaxel failed to cause significant 
PARP and caspase 3 cleavage in the other EOC cell lines.  This suggests that activation 
of apoptosis during mitosis may be defective in these cell lines as a result of reduced 
MAD2 expression.   
 
To further investigate the role of MAD2 in the activation of mitotic cell death in response 
to paclitaxel, MAD2 expression was knocked down in the A2780 cells by siRNA (Figure 
3c).  MAD2 knockdown cells were more viable in the presence of 10 and 50 nM 
paclitaxel compared to scrambled siRNA control cells (Figure 3c, left panel).  Moreover, 
MAD2 knockdown by siRNA abolished paclitaxel induced SAC activation and mitotic 
arrest as demonstrated by  the absence of cyclin B1 stabilsation and Histone H3 
phosphorylation (Figure 3c, right panel) in MAD2 siRNA transfected cells.  The 
activation of the apoptotic response resulting in PARP and caspase 3 cleavage was also 
inhibited in the MAD2 siRNA transfected cells compared to scrambled control 
transfected cells (Figure 3c, right panel). Overall, these results have demonstrated that 
paclitaxel induced SAC activation and the subsequent activation of apoptosis during 
mitosis in ovarian cancer cells is associated with high MAD2 protein expression.  
 
Pre-miR-433 causes downregulation of MAD2 protein expression and attenuates the 
cellular responses to paclitaxel in ovarian cancer cells.  microRNAs (miRs) are a large 
family of gene regulators, which constitute a novel class of non-coding RNA that bind to 
mRNA and result in either the degradation or inhibition of translation of their target 
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genes into protein (28).  In silico analysis using MicroCosm (previously mirBase) (29)  
demonstrated a putative miR-433 microRNA binding domain in the 3’UTR of the MAD2 
transcript (Figure 4a).  miR-433 expression was assessed in the 5 ovarian cancer cell lines 
by qRT-PCR (Figure 4b).  The ovarian cancer cell line, A2780 which expressed the 
highest level of MAD2 mRNA (Figure 2a) and protein expression levels (Figure 2b) 
displayed the lowest miR-433 expression levels (Figure 4b).  When comparing the A2780 
cell line with the other ovarian cancer cell lines, lower  MAD2 mRNA and protein levels 
(Figure 2a and 2b) were associated with concomitant higher miR-433 expression levels 
(Figure 4b).  Subsequently, we transiently transfected A2780 cells with the 70 bp 
precursor microRNA, pre-miR-433 (Figure 4c, top panel).  Pre-miR-433 resulted in the 
downregulation of MAD2 protein expression compared with the scrambled control pre-
miRs (Figure 4c, top panel) which lasted for 72 h in HeLa cells (Supplemental Figure 
1a).   
 
To investigate if miR-433 binds to the MAD2 3’UTR, we designed a morpholino 
oligonucleotide targeting the putative MAD2-miR-433 binding domain (Figure 4a).  The 
transient transfection of the MAD2 morpholino oligonucleotide caused an increase in 
MAD2 protein expression (Figure 4c, middle panel) and we conclude that the MAD2 
morpholino oligonucleotide protects from endogenous miR-433 by sterically hindering 
miR-433 from binding to the MAD2 3’UTR.  Finally, MAD2 protein expression was 
analysed in A2780 cells that were co-transfected with pre-miR-433 and the MAD2 
morpholino oligonucleotide and compared to cells transfected with pre-miR-433 alone.  
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The western blot analyses revealed that MAD2 protein expression was higher in the 
presence of the MAD2 morpholino oligonucleotide (Figure 4c, lower panel).   
 
Finally, the previously described pMIR-REPORT miRNA expression reporter vector 
system (30) for measuring mRNA-microRNA interactions was also used to investigate if 
miR-433 interacts with the MAD2 3’UTR.  Co-transfection of pre-miR-433 with pMIR-
REPORT vector containing the MAD2 3’UTR caused marked reduction in luciferase 
activity compared to scrambled control pre-miRs (Figure 4d).  Overall, these experiments 
demonstrate a functional interaction between miR-433 and MAD2 3’UTR.  Furthermore, 
blocking this binding site protects MAD2 from miR-433 induced protein downregulation. 
 
The transient transfection of pre-miR-433 attenuates paclitaxel responses in ovarian 
cancer cells.  Cellular responses to paclitaxel were investigated in A2780 cells 
transfected with pre-miR-433 by the MTT cell viability assay and western blot analyses.  
The downregulation of MAD2 by pre-miR-433 resulted in a decreased sensitivity to 10 
nM and 50 nM paclitaxel as judged by the MTT assay (Figure 5a).  The activation of the 
SAC and apoptosis in response to paclitaxel was also compromised in A2780 cells 
transfected with pre-miR-433 (Figure 5b).  Specifically, miR-433 induced 
downregulation of MAD2 protein expression, resulted in paclitaxel induced cyclin B1 
stabilisation (Figure 5b).  However, phosphorylation of Histone H3, PARP cleavage and 
cleaved caspase 3 levels were attenuated following treatment with paclitaxel compared to 
scrambled controls (Figure 5b compare lane 2 with lane 4).  Finally, the expression of 
miR-433 was analysed by RT-PCR and normalised to U6 in patient cohort 1 (n = 45).  
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The median expression level was 1.07.  For statistical analysis, miR433 was grouped by 
tertiles, as follows; low (< 0.7),  intermediate (range 0.7 – 1.8), and  high (> 1.8) miR-433 
expression.  The Kaplan Meier survival curve and log rank analysis revealed that high 
miR-433 was non-significantly associated with reduced PFS (p=0.078) (supplemental 
Figure 2).  
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Discussion 
 
The role of aberrant MAD2 expression and cellular drug resistance to chemotherapy 
agents has been studied extensively in cell culture models (31-34).  However, there are 
few published studies on human clinical cancer specimens.  In this manuscript we have 
demonstrated the novel association between low MAD2 IHC staining intensity and 
reduced PFS in high-grade serous EOC.  Moreover from the observation that MAD2 
positive ovarian epithelial cells co-exist with MAD2 negative ovarian cancer cells within 
the same tissue specimen, we hypothesise that the MAD2 negative ovarian epithelial cells 
are chemo-resistant which may explain the high propensity for EOC to recur.  Indeed, 
data presented in this study demonstrated that paclitaxel can no longer induce cell cycle 
arrest or apoptosis in ovarian cells devoid of MAD2.  While paclitaxel has provided the 
biggest single advance in the management of EOC over the last decade (35) paclitaxel is 
administered in combination with platinum based chemotherapy.  Therefore, the apparent 
prognostic value of MAD2 IHC staining documented in this study cannot be attributable 
to paclitaxel sensitivity alone.  Specifically, EOC is routinely stratified by chemo-
response to cisplatin (36).  As MAD2 was previously reported to mediate cellular 
responses to DNA-damaging agents in cancer cells (33), measuring MAD2 IHC staining 
intensity may also be predictive of chemo-response to cisplatin in EOC.   
 
Loss of BRCA1 significantly contributes to the pathogenesis of sporadic EOC and 
tumours with inactive BRCA1 are reported to have a better outcome due to improved 
responses to cisplatin (37).    Therefore, tumours with high MAD2 IHC intensity and very 
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long PFS are likely to be highly enriched for BRCA1 inactivation.  Conversely, loss of 
BRCA1 function is reported to be predictive of resistance to the taxanes (35).  BRCA1 
has been found to transcriptionally regulate the expression of MAD2 (38).   However, the 
degree of BRCA1 inactivation reportedly associated with EOC does not correlate with 
the high levels of MAD2 IHC measured in our study and other factors must also regulate 
MAD2 expression in EOC.  A recent study by Schvartzman et al., 2011 describes a 
tumour model where MAD2 becomes upregulated as a result of P53 inactivation resulting 
in Chromosomal Instability (CIN) (39).  P53 is frequently inactivated in EOC but its use 
as a biomarker of chemo-response in EOC is contentious (1, 35).  While it is not yet clear 
why MAD2 may be independently predicting PFS, we have demonstrated that MAD2 
expression is required to mediate chemo-responses in EOC cells and MAD2 negative 
cells are likely to be chemo-resistant. 
 
How MAD2 expression becomes downregulated by a microRNA was also demonstrated 
in our study and we report for the first time the downregulation of MAD2 protein 
expression by miR-433.  MiR-433 exists in a small cluster of 5 microRNAs which are 
located in the human imprinted 14q32 domain (40).  Furthermore, expression of 
microRNAs from this cluster is reported to be altered in cancer by epigenetic silencing 
(41, 42).  We propose that miR-433 expression becomes deregulated in ovarian cancer 
resulting in the down-regulation of MAD2 expression.  We hypothesise that this 
contributes to a poorer chemo-response in EOC as paclitaxel responses are attenuated in 
pre-miR-433 transfected cells as a result of MAD2 protein downregulation. 
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In summary, this study describes a micro-RNA-mediated mechanism by which ovarian 
cancer cells can become less sensitive to paclitaxel.  We suggest that profiling MAD2 
immunohistochemical staining intensity could predict chemo-response in women 
presenting with high-grade serous EOC.  Moreover, understanding chemo-responses in 
ovarian tumours will lead to improved patient management and treatment options for 
women diagnosed with this disease. 
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Figure Legends 
 
Figure 1: Nuclear MAD2 IHC staining intensity is associated with progression free 
survival (PFS) in high-grade serous EOC. a) Full face FFPE sections demonstrating 
IHC staining  intensity for MAD2, low (2+),  intermediate (3+), high (4+).  b) 
Multivariate Cox’s regression hazard analysis: correlation of low MAD2 IHC staining 
intensity expression with progression free survival (PFS) in patients with high-grade 
serous EOC. Multivariate Cox’s regression hazard analysis (adjusted for stage, tumour 
grade and optimum surgical debulking (< 1 cm) showed a signiﬁcant correlation between 
low MAD2 IHC staining intensity and PFS (p = 0.0003; HR 4.689) 
 
Figure 2. Ovarian cancer cells with low MAD2 protein expression are less sensitive 
to paclitaxel. a) Bar graph of qRT-PCR for MAD2 mRNA expression. Relative 
expression levels compared to A2780 cells were determined using the standard curve 
method (ABI Prism 7700 Sequence Detection System User Bulletin no. 2) and quantified 
using the TaqMan® comparative CT method of analysis.  b) Western blot analyses for 
MAD2 protein expression and western blot for -actin loading control. c) Line graph 
representing a dose response curve for cell viability assessed in a MTT assay in ovarian 
cancer cells treated with (1 - 500 nM paclitaxel for 48 h.  The data presented are 
representative of at least 3 independent experiments.  The student’s t test was used for 
comparison of means (*p<0.05, **p<0.01 and ***p<0.001). 
 
Figure 3. Cellular responses to paclitaxel are compromised in ovarian cells that 
express low levels of MAD2. a) Western blot analyses for cyclin B1, phospho(Ser10)-
Histone H3 and PARP cleavage, in the ovarian cancer cell lines treated with 10 and 50 
nM paclitaxel for 24 h.  b) Western blot analyses for PARP and cleaved caspase 3, in the 
ovarian cancer cell lines treated with 10 and 50 nM paclitaxel for 48 h.  A western blot 
for -actin was used as a loading control.  The data presented are representative of at 
least 3 independent experiments. c) MTT viability assay of A2780 cells transiently 
transfected with MAD2 siRNA and scrambled controls and treated with paclitaxel for 24 
h.  Western blot analyses of A2780 cells transiently transfected with MAD2 siRNA and 
scrambled controls and treated with paclitaxel for 24 h.  Data presented are representative 
of at least 3 independent experiments (*p <0.05, **p<0.01). 
 
 
Figure 4.  Binding of miR-433 to the 3’UTR of MAD2 mRNA dowregulates MAD2 
protein expression.  a) Schematic representation of the miR-433 binding region in the 
MAD2 3’UTR and the sequence of the MAD2 morpholino oligonucleotide 
complimentary to the miR-433-MAD2 binding domain.  b) Bar graph of relative miR-
433 gene expression in the ovarian cancer cell lines.  Relative expression levels compared 
to A2780 cells were determined using the standard curve method (ABI Prism 7700 
Sequence Detection System User Bulletin no. 2) and quantified using the TaqMan® 
comparative CT method of analysis.  c)  MAD2 and -actin-loading control western blot 
analyses of A2780 cell lines transfected with pre-miR-433 and scrambled controls or 
MAD2 morpholino and morpholino scrambled controls.  Bar graphs represent MAD2 
expression as a percentage of control measured by densitometry using ImageJ.  The data 
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presented are representative of at least 3 independent experiments.  d) Comparison of 
normalised luciferase activity in A2780 cells transfected with MAD2-pMIR-REPORT 
and pre-miR-scr or pre-miR-433. The student’s t test was used for comparison of means 
(*p <0.05, **p<0.01 and ***p<0.001). 
 
Figure 5. Transient transfection of pre-miR-433 compromises paclitaxel responses 
in A2780 cells. a) Bar graph representing the relative viability assessed by MTT assay in 
A2780 cells transiently transfected with pre-miR-433 and treated with 10 nM and 50 nM 
paclitaxel compared to scrambled control.  b) Western blot analyses for MAD2, cyclin 
B1, phospho(Ser10)-Histone H3, PARP cleavage and cleaved caspase 3 in A2780 cells 
transiently transfected with scrambled control microRNAs and pre-miR-433. The cell 
lines were treated with 10 nM and 50 nM paclitaxel for 24 h. A western blot for -actin 
was used to demonstrate loading.  The data presented are representative of at least 3 
independent experiments.  Mean differences were calculated in a student’s t test where 
statistical significance was assessed as *p <0.05.  
 
 
 
Supplemental Figure 1:  MAD2 western blot analysis of HeLa cells transiently 
transfected with pre-miR-433 and scrambled controls.   
 
 
Supplemental Figure 2:  Univariate Kaplan Meier survival curve: correlation of miR-
433 expression with progression free survival (PFS).  High miR-433 levels non-
significantly associate with reduced PFS (Log rank p=0.078). 
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Table 1. Clinicopathological details of ovarian specimens 
 
Abbreviations: ND, not documented. 
 
Full Face Sections (patient cohort 1)   Tissue Microarray Sections (patient cohort 2) 
Tumour Type Stage Grade No.  Tumour Type Stage Grade  No. 
Serous Adenocarcinoma I 3 3  Serous Adenocarcinoma I 2 1 
Serous Adenocarcinoma II 3 3  Serous Adenocarcinoma I 3 3 
Serous Adenocarcinoma III 2 2  Serous Adenocarcinoma I 4 1 
Serous Adenocarcinoma IIIA 3 1  Serous Adenocarcinoma II 2 2 
Serous Adenocarcinoma IIIB 2 1  Serous Adenocarcinoma II 3 11 
Serous Adenocarcinoma IIIB 3 1  Serous Adenocarcinoma III 2 1 
Serous Adenocarcinoma IIIC 2 10  Serous Adenocarcinoma III 3 18 
Serous Adenocarcinoma IIIC 3 16        
Serous Adenocarcinoma IIIC ND 3        
Serous Adenocarcinoma IV 3 4        
Serous Adenocarcinoma IV 2 1        
TOTAL    45   TOTAL     37 
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Table 2. Sequence of primers for cloning the MAD2 3’UTR 
Gene 
 name 
Primer sequence Accession 
number 
Location on 
transcript (bp) 
Size 
) 
MAD2 F: 5’ GGCCACTAGTCTACTACAATCCACAAAGTA 3’ 
R: 5’GGCCAAGCTTAACAAACTTAACTTTATTTC 3’ 
NM_002358 661 - 1381 ~700 
 
 
 
